Drugs /
omega-3 fatty acid
Overview
Clinical Trials
Omega-3 fatty acid has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating omega-3 fatty acid, 1 is no phase specified (1 open).
ER Negative, ER No Expression, and PR Negative are the most frequent biomarker inclusion criteria for omega-3 fatty acid clinical trials.
Breast carcinoma is the most common disease being investigated in omega-3 fatty acid clinical trials [2].
Drug Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].
2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.